Staphylococcus Aureus Clinical Trial
— CARRIEROfficial title:
Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial.
Verified date | October 2020 |
Source | Radboud University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial focusses on identifying the most effective and safe long-term S. aureus carriage decolonization strategy in home parenteral nutrition patients. Half of the participants will receive a quick and short systemic antibiotic treatment combined with topical treatment, while the other half will receive only topical treatment on a periodic basis.
Status | Terminated |
Enrollment | 63 |
Est. completion date | October 14, 2021 |
Est. primary completion date | October 14, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient is fully able to understand the nature of the proposed intervention. - Written informed consent by the patient before entering the trial. - Age = 18 years. - Estimated life expectancy = 1 year. - Patient colonized with S. aureus. Exclusion Criteria: - Cannot be expected to comply with the trial plan (substance abuse, mental condition). - Pregnant or breastfeeding women. - Continuous exposure to Methicillin-resistant S. aureus (MRSA; e.g. pig farmer). - Allergy for chlorhexidine and betadine. - No options for oral and/or topical antibiotics due to allergies. - Active S. aureus infection. - Currently on treatment with antibiotics active against S. aureus. - Decolonization (including mupirocin) treatment in the previous two months. - The presence of a nasal foreign body. - Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) levels more than five times the upper limit of normal or liver failure. |
Country | Name | City | State |
---|---|---|---|
Denmark | Aalborg Universitetshospital | Aalborg | |
Denmark | Rigshospitalet | Copenhagen | |
Netherlands | AMC | Amsterdam | Noord-Holland |
Netherlands | Radboud UMC | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University College, London, ZonMw: The Netherlands Organisation for Health Research and Development |
Denmark, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients totally eradicated for S. aureus during one year | Totally eradicated is defined as 100% of all culture swabs (nose, throat, rectum), exit-site catheter and body regions on indication) being negative for S. aureus. | One year | |
Secondary | Proportion of patients totally eradicated after one year | Proportion of patients totally eradicated for S. aureus based on negative cultures performed after one year | One year | |
Secondary | Developing long-term antimicrobial resistance | Long-term antimicrobial resistance at 6 and 12 months (measured with standard cultures and NGS) | 6 and 12 months | |
Secondary | Incidence of S. aureus infections | Incidence of S. aureus infections measured with (serious) adverse events forms every 3 months | Every 3 months during one year | |
Secondary | Overall incidence of infections | Overall incidence and time to onset of infections measured with (serious) adverse events forms every 3 months | Every three months during one year | |
Secondary | Number of catheter removals | Number of catheter removals based on data from electronic patient dossier | One year | |
Secondary | Mortality | Mortality based on data from electronic patient dossier | One year | |
Secondary | S. aureus transmission | S. aureus transmission routes from caregiver to patient (measured with NGS). | One year | |
Secondary | Patient compliance | Patient compliance (measured with medication files, counting pills, trial-specific medication diary). | Every three months during one year | |
Secondary | Adverse events | Adverse events (measured with (serious) adverse event forms every 3 months). | Every three months during one year | |
Secondary | Predictors for infections and treatment outcome | Predictors for infections and treatment failure/success (binominal regression analysis). | One year | |
Secondary | Health related quality of life | Generic health related quality of life (measured with a validated questionnaire (EQ5D-5L)). | 0, 6 and 12 months | |
Secondary | Healthcare related costs. | Cost-effectiveness analysis | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05073926 -
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
|
||
Completed |
NCT01212120 -
The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections
|
N/A | |
Completed |
NCT00801879 -
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
|
Phase 4 | |
Terminated |
NCT03638947 -
Reducing Perioperative S. Aureus Transmission
|
N/A | |
Recruiting |
NCT05331885 -
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
|
Phase 3 | |
Recruiting |
NCT05094570 -
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
|
Phase 4 | |
Not yet recruiting |
NCT05092464 -
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
|
N/A | |
Recruiting |
NCT05695196 -
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04666532 -
S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
|
||
Active, not recruiting |
NCT02572791 -
Staph Household Intervention for Eradication (SHINE)
|
Phase 4 | |
Recruiting |
NCT04274348 -
Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum
|
N/A | |
Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
Completed |
NCT01011335 -
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
|
Phase 1/Phase 2 | |
Completed |
NCT03816956 -
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
|
Phase 3 | |
Not yet recruiting |
NCT04884958 -
A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
|
||
Completed |
NCT01105767 -
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
|
N/A | |
Completed |
NCT00475930 -
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates
|
N/A | |
Completed |
NCT00507247 -
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
|
Phase 2 | |
Recruiting |
NCT03220386 -
Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making
|
N/A | |
Completed |
NCT03140423 -
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
|
Phase 4 |